Vir Biotechnology, Inc.’s Post

In case you missed it, Mitchell Shiffman, M.D. discussed the results from our Phase 2b #AHFIRM trial in alcohol-associated #hepatitis (#AH) in a late-breaking oral presentation at the EASL Congress 2024. We're excited to advance into a Phase 3 #ClinicalTrial. See the slides here: https://bit.ly/3Rq8m4E EASL | The Home of Hepatology

🔈 BIG NEWS! DECISION has enrolled the first patient at Hôpital Beaujon, Clichy, France in the COMBAT Trial, a multicenter, randomized, open-label, Phase II clinical trial. This trial is a crucial component of the DECISION project, which aims to transform the treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF), investigating albumin and enoxaparin, a potential combinatorial therapy for decompensated cirrhosis. Read more in our press release: https://lnkd.in/dcsrwc54 Pierre-Emmanuel Rautou Greater Paris University Hospitals - AP-HP CARACENI Paolo Alma Mater Studiorum – Università di Bologna European Foundation for the Study of Chronic Liver Failure (EF CLIF) EASL | The Home of Hepatology #COMBATtrial #hepatology #cirrhosis #decompensation #ACLF #liver #Albumin #Enoxaparin #ClinicalTrial #PhaseIItrial #SciComm 

An article published in Pancreatology by Somashekar Krishna, a key clinical investigator for our mucinous pancreatic cyst clinical trial, reports further insights from a follow-on expanded access protocol he led of intracystic LSAM-PTX in pts with nonoperable high-risk BD-IPMNs. https://lnkd.in/gQSjCs-E

Gulf & Mena Hepatobiliary conference Our case report highlights a rare presentation of a perforated liver abscess https://lnkd.in/dwuhhN9X

Wow, so this is a thing! Finally some promising results of clinical trials with bacteriophages! Thank you for this amazing progress, BiomX Inc https://lnkd.in/dq_gd9FW Having statistically well evaluated results of the clinical trials is an essential step to persuade more not-so-involved people, that phage therapy works. Let's wait what happened after (hopefully successful) phase III. #phagetherapy #clinicaltrials #bacteriophages

Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Expand Phase 2b MOVE-IT Study in Gastroparesis 🌍 Renexxion Ireland Ltd., in partnership with Dr. Falk Pharma GmbH, has announced the expansion of their Phase 2b MOVE-IT study to include the United States, marking a significant milestone in the development of naronapride for the treatment of gastroparesis. This global study, which began dosing patients in Europe in February 2023, has now dosed its first U.S. patient following the recent FDA IND clearance. 🚀 The MOVE-IT study aims to evaluate the safety and efficacy of naronapride, an innovative treatment for gastroparesis, a gastrointestinal disorder with high unmet medical needs. This expansion underscores the commitment of both companies to advancing solutions for GI disorders and improving patient outcomes on a global scale. 🌟 At Hanley, we are impressed by Renexxion Ireland Ltd.'s expansion of the Phase 2b MOVE-IT study to the U.S. in collaboration with Dr. Falk Pharma GmbH. This global initiative, now including U.S. patients following FDA IND clearance, represents a significant step in advancing naronapride for gastroparesis treatment. #ClinicalTrials #Gastroenterology #Renexxion #DrFalkPharma #HanleyAutomation

When do you refer for SBRT in the treatment for HCC? A/Prof David Pryor joins Dr Lucinda Vaux to discuss practicalities, indications and post-treatment changes in the latest episode of 7 minute hepatology.

DefiniGEN's iPSC-derived hepatocytes (Opti-Heps) are superior to current pre-clinical models (HepG2 and Primary Human Hepatocytes). Come and find out why. To schedule a meeting https://lnkd.in/et6i-h5y #ipsc #liverdisease #slas

Recently, I had the privilege of meeting a woman who spent decades awaiting a diagnosis for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease. This is not just her story. More than 115 million people around the world are living with MASH. Why should we pay attention to this? Due to progressive liver damage that can develop silently, MASH can often go undiagnosed for years. MASH is projected to become the leading cause of liver transplantation by 2030. Each delayed diagnosis is a missed opportunity for early intervention and improved patient outcomes. This underscores the urgent need for innovation in MASH. It is through such advancements that we could transform patient stories from journeys of uncertainty to narratives of hope and healing. Let's continue to push the boundaries of what's possible in healthcare, for the sake of patients worldwide. Today’s announcement of potential best-in-class data is pivotal in our mission to improve the lives of people living with MASH and liver fibrosis. I’m proud of the team for achieving this critical Phase II milestone! #EASLCongress #liverdisease #NEWS

In case you missed it Get an update on emerging therapies based on protein degradation and immunomodulation for relapsed/refractory multiple myeloma, including the latest data and ongoing clinical trials. Learn more with Prof. Cristina Gasparetto, Prof. Sagar Lonial and Prof. Sundar Jagannath: https://lnkd.in/emK-FWH2 This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME. #MultipleMyeloma #Immunomodulation #Myeloma #ClinicalTrials #Therapies #RRMM